An oncolytic virus-based drug JX-594 (also called Pexa-Vec) is highly effective in patients with advanced hepatocellular carcinoma. According to the results of a Phase II clinical trial published online at Nature Medicine journal's website on February 10, 2013, the patients who were given higher (more effective) dose of JX-594 had a median survival of 14.1 months which was twice that seen in the low dose group (6.7 months).
Oncology targets, strategies, cancer drug development and personalized medicine
Showing posts with label cancer immunology. Show all posts
Showing posts with label cancer immunology. Show all posts
Tuesday, February 19, 2013
Wednesday, April 11, 2012
Focus on Tumour immunology & immunotherapy from Nature Reviews Cancer and Nature Reviews Immunology
The tumour microenvironment is an important aspect of cancer biology that contributes to tumour initiation, tumour progression and responses to therapy. Cells and molecules of the immune system are a fundamental component of the tumour microenvironment.
Subscribe to:
Posts (Atom)